Treace Medical: the coordinated inflection
Case volumes, a 30% pull-through, and a fresh $300M midfoot TAM are scheduled to convert the ASP-mix trough into Q4 growth — and the tape is already up ~140%.
TMCI · Earnings Call · 2026-08-07
The engineered valley
Around the midpoint of a deliberately buried year, Treace Medical's story has turned from defense to scheduling. Second-quarter revenue fell 4% to $45.4M, a decline management attributed to "lower procedure kit sales to stocking distributors and a continued mix shift towards lower-priced minimally invasive products." But the framing was unmistakably offensive: “we accelerated our case volume growth. We talked about mid-single digits over the last couple of quarters. We were in the high single digits this quarter” — John Treace, Chief Executive Officer · 2026-08-07 — and the company nudged its full-year revenue guide to $204M-$212M while confirming the annualized mix headwind laps this quarter, setting up the seasonally dominant fourth quarter to finally print positive growth. The market has already priced that calendar: TMCI has rallied roughly 140% over the last 90 trading days, a +133% move across ten weeks, even as the quarterly income statement still shows a $15.9M net loss. This is not a company reporting a turnaround; it is a company reporting the schedule of one.Adoption is now measurable
The heart of the bull narrative is numeric progress on surgeon adoption. Roughly 40% of the Lapiplasty surgeon base has now used at least one of the three bunion systems launched in Q3 2025, up from 35% in the first quarter — and, critically, the new-cohort cascade is reaching the legacy franchise. John Treace: “approximately 30% of the growing number of new surgeons who first became Treace customers by using 1 of our 3 new bunion systems have also used Lapiplasty technology, demonstrating a pull-through effect to Lapiplasty technologies from this new surgeon cohort.” — John Treace, Chief Executive Officer · 2026-08-07 That answers directly the question posed on the prior call, when the company hedged it was "too early to say what the materiality of that is going to be." Now management has put a number on it — evidence of genuine bunion market share-taking rather than in-base cannibalization.The mix hand-off, on schedule
The persistent drag is the ASP mix: new MIS osteotomy systems carry lower price points than Lapiplasty, so higher case counts do not immediately lift the top line. But the headwind has a fixed expiry. As CFO Mark Hair flagged in May, when the new products' anniversary arrives “it's really in the third quarter of this year” — Mark Hair, Chief Financial Officer · 2026-05-08 that the dynamic begins to abate. With the calendar clearing, the step-up into bunion season should convert volume momentum into revenue growth — Mark confirmed the intended cadence this quarter, stating “we will have a step-up in the third quarter versus Q2.” — Mark Hair, Chief Financial Officer · 2026-08-07The midfoot platform changes the basket
The most distinctive development was forced quantification of the adjacency story. SuperBite compression screw entered limited release in Q2 and fully commercializes this quarter; HyperPlate XM and GreatReleaseXM round out the midfoot/hindfoot fusion toolkit, with CartiBlaster arriving in Q4. On the quarter, John put a fresh number on the expansion:That is the first time the company has sized the foot-and-ankle expansion beyond bunions, and it recasts the conversation from addressable market saturation to wallet share in adjacent procedures — each incremental SuperBite case often pulls additional Treace products with it.When you look at the combination of SuperBite, the HyperPlate XM and the CartiBlaster, GreatReleaseXM platform, we think that expands our TAM by about $300 million on the U.S. side.